LSE:AZN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide.


Snowflake Analysis

High growth potential average dividend payer.


Similar Companies

Share Price & News

How has AstraZeneca's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AZN has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-1.1%

AZN

-2.0%

GB Pharmaceuticals

-1.5%

GB Market


1 Year Return

35.3%

AZN

16.1%

GB Pharmaceuticals

-14.9%

GB Market

Return vs Industry: AZN exceeded the UK Pharmaceuticals industry which returned 15.6% over the past year.

Return vs Market: AZN exceeded the UK Market which returned -15.5% over the past year.


Shareholder returns

AZNIndustryMarket
7 Day-1.1%-2.0%-1.5%
30 Day4.5%2.6%0.9%
90 Day12.6%8.1%7.5%
1 Year39.5%35.3%20.5%16.1%-10.9%-14.9%
3 Year89.5%70.0%46.8%29.6%-4.0%-15.8%
5 Year140.5%97.1%83.4%47.3%13.6%-11.8%

Price Volatility Vs. Market

How volatile is AstraZeneca's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is AstraZeneca undervalued compared to its fair value and its price relative to the market?

33.4%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AZN (£85.68) is trading below our estimate of fair value (£128.7)

Significantly Below Fair Value: AZN is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AZN is poor value based on its PE Ratio (93.4x) compared to the GB Pharmaceuticals industry average (15.4x).

PE vs Market: AZN is poor value based on its PE Ratio (93.4x) compared to the UK market (15.2x).


Price to Earnings Growth Ratio

PEG Ratio: AZN is poor value based on its PEG Ratio (3.1x)


Price to Book Ratio

PB vs Industry: AZN is overvalued based on its PB Ratio (13.2x) compared to the GB Pharmaceuticals industry average (3.6x).


Next Steps

Future Growth

How is AstraZeneca forecast to perform in the next 1 to 3 years based on estimates from 21 analysts?

30.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: AZN's forecast earnings growth (30.3% per year) is above the savings rate (1.2%).

Earnings vs Market: AZN's earnings (30.3% per year) are forecast to grow faster than the UK market (21.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: AZN's revenue (11.4% per year) is forecast to grow faster than the UK market (3.3% per year).

High Growth Revenue: AZN's revenue (11.4% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: AZN's Return on Equity is forecast to be very high in 3 years time (46.8%).


Next Steps

Past Performance

How has AstraZeneca performed over the past 5 years?

-1.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AZN has high quality earnings.

Growing Profit Margin: AZN's current net profit margins (6%) are lower than last year (10.7%).


Past Earnings Growth Analysis

Earnings Trend: AZN's earnings have declined by -1.2% per year over the past 5 years.

Accelerating Growth: AZN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: AZN had negative earnings growth (-36.7%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (26%).


Return on Equity

High ROE: AZN's Return on Equity (11.6%) is considered low.


Next Steps

Financial Health

How is AstraZeneca's financial position?


Financial Position Analysis

Short Term Liabilities: AZN's short term assets ($12.8B) do not cover its short term liabilities ($17.0B).

Long Term Liabilities: AZN's short term assets ($12.8B) do not cover its long term liabilities ($28.0B).


Debt to Equity History and Analysis

Debt Level: AZN's debt to equity ratio (166.4%) is considered high.

Reducing Debt: AZN's debt to equity ratio has increased from 61.7% to 166.4% over the past 5 years.

Debt Coverage: AZN's debt is not well covered by operating cash flow (17.2%).

Interest Coverage: AZN's interest payments on its debt are well covered by EBIT (5.6x coverage).


Balance Sheet


Next Steps

Dividend

What is AstraZeneca current dividend yield, its reliability and sustainability?

2.58%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: AZN's dividend (2.58%) is higher than the bottom 25% of dividend payers in the UK market (1.96%).

High Dividend: AZN's dividend (2.58%) is low compared to the top 25% of dividend payers in the UK market (5.46%).


Stability and Growth of Payments

Stable Dividend: AZN's dividends per share have been stable in the past 10 years.

Growing Dividend: AZN's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its high payout ratio (241.4%), AZN's dividend payments are not well covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: AZN's dividends in 3 years are forecast to be well covered by earnings (43.9% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

7.1yrs

Average management tenure


CEO

Pascal Soriot (61yo)

7.75yrs

Tenure

US$14,330,000

Compensation

Mr. Pascal Soriot, MBA has been the Chief Executive Officer and Executive Director at AstraZeneca PLC since October 1, 2012. Mr. Soriot served as the Chief Operating Officer of Roche Pharma AG from 2010 to ...


CEO Compensation Analysis

Compensation vs Market: Pascal's total compensation ($USD18.12M) is above average for companies of similar size in the UK market ($USD4.70M).

Compensation vs Earnings: Pascal's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Pascal Soriot
CEO & Executive Director7.75yrsUS$14.33m0.0097% $10.9m
Marc Dunoyer
CFO & Executive Director6.67yrsUS$6.96m0.013% $14.3m
Pam Cheng
Executive Vice-President of Operations & Information Technology5.08yrsno datano data
Ralph Knöll
Chief Scientist0.92yrno datano data
Thomas Larsen
Head of Investor Relationsno datano datano data
Jefrey Pott
General Counsel11.5yrsno datano data
Katarina Ageborg
Executive VP of Sustainability & Chief Compliance Officer9yrsno datano data
Fiona Cicconi
Executive Vice President of Human Resources5.83yrsno datano data
Menelas Pangalos
Executive Vice-President of BioPharmaceuticals Research & Development7.5yrsno datano data
Ruud Dobber
Executive Vice-President of BioPharmaceuticals Business Unit7.5yrsno datano data
Susan Galbraith
Senior VP and Head of Researchno datano datano data
David Goldstein
Chief Adviser3.83yrsno datano data

7.1yrs

Average Tenure

57.5yo

Average Age

Experienced Management: AZN's management team is seasoned and experienced (7.1 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Pascal Soriot
CEO & Executive Director7.75yrsUS$14.33m0.0097% $10.9m
Marc Dunoyer
CFO & Executive Director6.67yrsUS$6.96m0.013% $14.3m
Marcus Wallenberg
Non-Executive Director21.25yrsUS$103.00k0.0046% $5.1m
Leif Johansson
Independent Non-Executive Chairman8.08yrsUS$697.00k0.0030% $3.3m
Philip John Broadley
Independent Non-Executive Director3.25yrsUS$144.00k0.00044% $494.7k
Graham Chipchase
Senior Independent Non-Executive Director1.5yrsUS$158.00k0.00023% $258.6k
Michel Demare
Independent Non-Executive Director0.83yrUS$36.00k0.000050% $56.2k
Deborah DiSanzo Eldracher
Independent Non-Executive Director2.58yrsUS$108.00k0.000080% $89.9k
Sherilyn S. McCoy
Independent Non-Executive Director2.75yrsUS$123.00k0.00013% $146.2k
Geneviève Berger
Independent Non-Executive Director8.25yrsUS$110.00k0.00016% $179.9k
Shu Kam Mok
Independent Non-Executive Director1.5yrsUS$103.00k0.000080% $89.9k
Nazneen Rahman
Independent Non-Executive Director3.08yrsUS$118.00k0.000040% $45.0k

3.2yrs

Average Tenure

61yo

Average Age

Experienced Board: AZN's board of directors are considered experienced (3.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

AstraZeneca PLC's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AstraZeneca PLC
  • Ticker: AZN
  • Exchange: LSE
  • Founded: 1992
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£112.435b
  • Shares outstanding: 1.31b
  • Website: https://www.astrazeneca.com

Number of Employees


Location

  • AstraZeneca PLC
  • 1 Francis Crick Avenue
  • Cambridge Biomedical Campus
  • Cambridge
  • Cambridgeshire
  • CB2 0AA
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AZNNYSE (New York Stock Exchange)ADR EACH REP 1 ORD USD0.25(MGT)USUSDMay 1993
AZNC.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDMay 1993
AZNLSE (London Stock Exchange)YesOrdinary SharesGBGBPMay 1993
AZNOM (OMX Nordic Exchange Stockholm)YesOrdinary SharesSESEKMay 1993
AZN NBMV (Bolsa Mexicana de Valores)ADR EACH REP 1 ORD USD0.25(MGT)MXMXNMay 1993
ZEGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMay 1993
ZEGADB (Deutsche Boerse AG)ADR EACH REP 1 ORD USD0.25(MGT)DEEURMay 1993
AZNSBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBSEKMay 1993
ZEGXTRA (XETRA Trading Platform)YesOrdinary SharesDEEURMay 1993
AZNSWX (SIX Swiss Exchange)YesOrdinary SharesCHCHFMay 1993
AZNLBATS-CHIXE (BATS 'Chi-X Europe')YesOrdinary SharesGBGBPMay 1993

Biography

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company’s marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/13 20:50
End of Day Share Price2020/07/13 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.